On July 12, 2024, Trinity Biotech Entered Into An ATM Offering Agreement With Craig-Hallum Capital Group, Pursuant To Which May Sell Up To $5.5M Of Its ADSs, Each ADS Representing 20 Of The Company's A Ordinary Shares (Co Will Also Pay Craig-Hallum A Commission Equal To 3% Of The Gross Sales Price Of ADSs)

On July 12, 2024, Trinity Biotech plc (the "Company") entered into an At the Market Offering Agreement (the "Sales Agreement") with Craig-Hallum Capital Group LLC ("Craig-Hallum"), pursuant to which the Company may sell up to $5,500,000 of its American Depositary Shares ("ADSs"), each ADS representing 20 of the Company's A Ordinary Shares, par value $0.0109 per share, from time to time, through Craig-Hallum, acting as sales agent.

Subject to the terms and conditions of the Sales Agreement, the Company will, from time to time, set the parameters for the sale of ADSs, including any price, time or size limits or other customary parameters or conditions, and Craig-Hallum will use its commercially reasonable efforts to sell the ADSs when requested by the Company. The Sales Agreement is filed herewith as Exhibit 1.1.

In the Sales Agreement, the Company has agreed to provide Craig-Hallum with customary indemnification rights. The Company will also pay Craig-Hallum a commission equal to 3.0% of the gross sales price of ADSs sold pursuant to the Sales Agreement.

Sales of the ADSs under the Sales Agreement may be made by any method permitted by law deemed to be an "at the market offering" as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.